Avacopan Better than Prednisone for Patients with AAV, Study Shares
freegr / Pixabay

Avacopan Better than Prednisone for Patients with AAV, Study Shares

Recently, the American College of Rheumatology (ACR) virtually held ACR Convergence 2020, the organization's annual meeting. At the meeting, researchers shared new insights in the realm of rheumatology; these were…

Continue Reading Avacopan Better than Prednisone for Patients with AAV, Study Shares
EMA Approves MAA Review of Avacopan for ANCA-Associated Vasculitis
source: pixabay.com

EMA Approves MAA Review of Avacopan for ANCA-Associated Vasculitis

On November 3, 2020, biopharmaceutical company ChemoCentryx and global pharmaceutical company Vifor Pharma Group's sub-business Vifor Fresenius Medical Care Renal Pharma (VFMCRP) announced that the European Medicines Agency will review…

Continue Reading EMA Approves MAA Review of Avacopan for ANCA-Associated Vasculitis
Atypical Hemolytic Uremic Syndrome Patients: There’s a new Medicine Coming to the Market!
https://pixabay.com/en/medicine-pills-bottles-medical-296966/

Atypical Hemolytic Uremic Syndrome Patients: There’s a new Medicine Coming to the Market!

ChemoCentrx has been working to develop a drug to combat auto-antibody-associated vasculitis (AAV), C3 glomerulopathy (C3G), and atypical hemolytic uremic syndrome (aHUS). Its name- Avacopan. ChemoCentryx has always had a…

Continue Reading Atypical Hemolytic Uremic Syndrome Patients: There’s a new Medicine Coming to the Market!